Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44362 | 0.77 | PTGS1 (0.32) | — | |
| SCHEMBL9347058 | 0.76 | ALOX15 (0.33) | — | |
| SCHEMBL9056289 | 0.74 | — | — | |
| SCHEMBL44241 | 0.74 | APP (0.37) | — | |
| SCHEMBL43569 | 0.73 | TSHR (0.39) | — | |
| SCHEMBL43703 | 0.71 | TSHR (0.38) | — | |
| SCHEMBL43898 | 0.71 | TSHR (0.38) | — | |
| SCHEMBL43986 | 0.71 | TSHR (0.38) | — | |
| SCHEMBL7717817 | 0.70 | — | — | |
| SCHEMBL992848 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708765-B1 | BIOCOMPATIBLE POLYMERIZATION ACCELERATORS | SURMODICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8202833-B2 | Coating of polymer containing N-vinyl groups on cells, tissue | SURMODICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7968614-B2 | Macromer composition including light activated initiator | SURMODICS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1893162-A2 | MACROMER COMPOSITION INCLUDING LIGHT ACTIVATED INITIATOR | SurModics, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138542-A2 | MACROMER COMPOSITION INCLUDING LIGHT ACTIVATED INITIATOR | SURMODICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287410-A1 | Macromer composition including light activated initiator | SURMODICS, INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1708765-A2 | BIOCOMPATIBLE POLYMERIZATION ACCELERATORS | SurModics, Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005054304-A2 | BIOCOMPATIBLE POLYMERIZATION ACCELERATORS | SURMODICS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050112086-A1 | Biocompatible polymerization accelerators | SURMODICS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112086-A1 | Biocompatible polymerization accelerators | VCL, PCNA, CD38 | ACP1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.